Skip to main content
Clinical Trials/NCT05664971
NCT05664971
Completed
Phase 1

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab and With Standard Chemotherapy in Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.1 site in 1 country119 target enrollmentFebruary 9, 2023

Overview

Phase
Phase 1
Intervention
Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection
Conditions
Advanced Lung Cancer
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Enrollment
119
Locations
1
Primary Endpoint
Incidence of SAEs
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with advanced lung cancer

Registry
clinicaltrials.gov
Start Date
February 9, 2023
End Date
October 23, 2025
Last Updated
5 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects are eligible for the study if they meet all of the following criteria:
  • Sign the informed consent form voluntarily;
  • Males or females ≥18 years at the time of signing the informed consent;
  • Expected survival ≥3 months;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ;
  • Pathologically confirmed locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), which is currently not suitable for local treatment such as radical surgery or radiotherapy; For subjects with non-squamous carcinoma, there is no EGFR sensitive mutation or ALK fusion; for subjects with squamous carcinoma, genetic testing is not mandatory
  • Pathologically confirmed extensive-stage small cell lung cancer (ES-SCLC, according to the Veterans Administration Lung Study Group (VALG) staging), previously received no systemic anti-tumor therapy for ES-SCLC (Cohort 5); Subjects with limited-stage SCLC who have previously received systemic anti-tumor therapy cannot be enrolled;
  • The subject has at least one measurable lesion as a target lesion (RECIST v1.1 criteria,);
  • The subject agrees to provide tumor tissue samples ;
  • The subject has good organ function as indicated by screening laboratory results:

Exclusion Criteria

  • Subjects who met any of the following criteria will be excluded from the study:
  • For the third line and second line populations with advanced lung squamous carcinoma (Cohorts 1 and 2), subjects who have received systemic anti-tumor therapy within 3 weeks before the first dose of study drug, including: chemotherapy, targeted therapy, anti-vascular drug therapy, biological therapy, immunotherapy, radiotherapy or other treatments with investigational products
  • Any adverse reactions caused by previous treatments have not recovered to CTCAE (Version 5.0) Grade 1 or below ;
  • Symptomatic metastases to central nervous system.;
  • Subjects with poorly controlled tumor-related pain who require analgesic treatment must receive the treatment at a stable dose before participating in the study;
  • Hydrothorax or ascites or pericardial effusion with clinical symptoms or unstable condition after symptomatic treatment;
  • Subjects previously discontinued treatment due to PD-1/PD-L1 inhibitor toxicity;
  • Known history of severe allergic reactions to JS004 or toripalimab and its components, scheduled chemotherapeutic drugs and their components;
  • Known active or suspected autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease;
  • History of interstitial lung disease or drug-induced interstitial lung disease or pulmonitis;

Arms & Interventions

Cohort 1

NSCLC-squamous carcinoma third line;JS004 200mg + JS001 240mg Q3w, maintained until disease progression

Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection

Cohort 1

NSCLC-squamous carcinoma third line;JS004 200mg + JS001 240mg Q3w, maintained until disease progression

Intervention: Toripalimab

Cohort 2

NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression

Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection

Cohort 2

NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression

Intervention: Toripalimab

Cohort 2

NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression

Intervention: Docetaxel

Cohort 3

NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression

Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection

Cohort 3

NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression

Intervention: Toripalimab

Cohort 3

NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression

Intervention: Pemetrexed

Cohort 3

NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression

Intervention: Cisplatin

Cohort 3

NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression

Intervention: Carboplatin

Cohort 4

NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection

Cohort 4

NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Toripalimab

Cohort 4

NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Carboplatin

Cohort 4

NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Paclitaxel

Cohort 5

SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection

Cohort 5

SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Toripalimab

Cohort 5

SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Cisplatin

Cohort 5

SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Carboplatin

Cohort 5

SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Intervention: Etoposide

Outcomes

Primary Outcomes

Incidence of SAEs

Time Frame: 2 years

Incidence of serious adverse events (SAEs)

Incidence of adverse events (AEs)

Time Frame: 2 years

Incidence of adverse events (AEs)

ORR

Time Frame: 2 years

Efficacy endpoint: objective response rate (ORR) based on RECIST v1.1 criteria

Incidence of irAEs

Time Frame: 2 years

Incidence of immune-related adverse events (irAEs)

Secondary Outcomes

  • titer of ADA(2 years)
  • time to response (TTR)(2 years)
  • PFS(2 years)
  • 1-year OS rate(1 year)
  • incidence of ADA(2 years)
  • incidence of Nab(2 years)
  • DOR(2 years)
  • titer of Nab(2 years)
  • DCR(2 years)
  • OS(2 years)
  • Drug concentration in plasma(2 years)

Study Sites (1)

Loading locations...

Similar Trials